A comprehensive systematic review and meta-analysis published in the Journal of Neuro-Oncology has evaluated the comparative outcomes of pre-operative stereotactic radiosurgery and intraoperative cesium-131 brachytherapy for patients undergoing surgical resection of newly diagnosed brain metastases. Metastatic tumors involving the central nervous system represent a primary source of morbidity and mortality in adult oncology, historically managed through surgical resection followed by adjuvant whole-brain radiotherapy to maintain intracranial disease control. While clinical investigations such as the trial conducted by Patchell and colleagues confirmed that whole-brain radiation suppressed intracranial recurrence following surgical excision, subsequent evaluations linked the modality to substantial neurocognitive toxicity. In response to these adverse effects and supported by technological developments in focal radiation delivery, clinical practices broadly transitioned toward post-operative stereotactic radiosurgery as the favored adjuvant standard of care across oncology centers.
Despite its widespread adoption, post-operative stereotactic radiosurgery possesses well-documented limitations that complicate therapeutic delivery. Radiosurgery administered following resection often involves delays between the surgical procedure and the initiation of radiation therapy, during which microscopic residual disease may advance. The irregular and variable morphology of post-resection cavities, accompanied by structural remodeling and uncertainty regarding target contouring across surgical corridors, presents challenges for radiation oncologists. Established consensus guidelines recommend applying expansions to the clinical target volume along the dura and surgical tract, which inevitably enlarges the volume of normal brain tissue subjected to radiation exposure. Furthermore, post-operative cavity irradiation carries a defined risk of secondary leptomeningeal disease dissemination and radiation necrosis, alongside the necessity for dose de-escalation when managing larger operative cavities.
In response to these clinical hurdles, researchers have advanced pre-operative stereotactic radiosurgery and intraoperative cesium-131 brachytherapy as alternative management strategies. Administering stereotactic radiosurgery prior to surgical resection allows radiation oncologists to target intact, spherical tumors with well-defined margins, thereby improving target delineation, conformity, and gradient indices while omitting cavity volume expansions. Devitalizing tumor cells prior to surgical manipulation may also diminish the intraoperative shedding of viable tumor cells into circulating cerebrospinal fluid pathways, although the pre-operative workflow requires radiation planning before surgery and is unsuitable for patients presenting with neurological deterioration requiring emergent decompression. Conversely, intraoperative cesium-131 brachytherapy, delivered via stranded seeds or collagen-embedded tiles placed directly into the cavity bed, initiates therapeutic radiation immediately at resection, eliminating external-beam delays and separate treatment courses.
To rigorously examine these two strategies, an investigative team led by Trent Kite and colleagues performed a systematic review adhering to PRISMA 2020 guidelines, screening records across PubMed/MEDLINE, Embase, and ScienceDirect through October 2026. After retrieving and evaluating candidate full-text articles and identifying one additional trial during protocol tracking, nineteen independent studies met all defined inclusion criteria. These encompassed fifteen studies evaluating pre-operative stereotactic radiosurgery comprising 918 patients and 940 brain metastases, and four prospective studies investigating intraoperative cesium-131 brachytherapy comprising 207 patients and 217 brain metastases. Across the cohort, lung cancer constituted the predominant primary malignancy in twelve of fifteen stereotactic radiosurgery reports and across all four brachytherapy studies, with median patient ages of 62 years and 64 years reported for the respective modalities.
The meta-analysis established twelve-month local control as its primary clinical endpoint, reflecting the conventional benchmark employed across surgical cavity radiosurgery research. Secondary endpoints extracted for pooled analysis comprised leptomeningeal disease, radiation necrosis, and overall survival across treatment-naïve cohorts. Event counts were pooled on the logit scale using binomial-normal generalized linear mixed models with modality-specific between-study variances to accommodate differing levels of heterogeneity without relying on artificial continuity corrections. For studies lacking raw event counts, researchers mathematically reconstructed twelve-month counts by applying published Kaplan–Meier or cumulative incidence percentages to analyzed denominators. Between-modality outcomes were formally evaluated using tests for subgroup differences, complemented by secondary mixed-effects meta-regressions and inverse-variance logit pooling models incorporating Hartung–Knapp adjustments.
In the primary pooled synthesis, twelve-month local control reached 97 percent, with a 95 percent confidence interval spanning 90 to 99 percent, among the four cesium-131 brachytherapy studies. Pre-operative stereotactic radiosurgery achieved a pooled twelve-month local control proportion of 90 percent across fourteen contributing studies, with a 95 percent confidence interval ranging from 86 to 93 percent. The primary test for subgroup differences yielded a borderline statistical difference between the two approaches, showing a p-value of 0.054, while meta-regression indicated a statistically significant difference with a p-value of 0.019 and the Hartung–Knapp model yielded a p-value of 0.066. Sensitivity analyses restricted to studies reporting directly observed event counts demonstrated twelve-month local control rates of 99 percent for brachytherapy compared with 90 percent for radiosurgery, achieving statistical significance with a p-value of 0.009.
Detailed subgroup assessments within the pre-operative radiosurgery cohorts demonstrated that radiation fractionation strongly influenced tumor control at twelve months. In pre-operative stereotactic radiosurgery studies utilizing hypofractionated multi-session regimens, pooled local control reached 96 percent, with an exact count of 110 controlled lesions among 114 patients across three studies. In contrast, pre-operative cohorts receiving single-fraction stereotactic radiosurgery demonstrated a pooled twelve-month local control rate of 86 percent, representing 214 controlled lesions among 250 patients across seven studies. This observed difference between fractionation schedules was statistically significant, yielding a p-value of 0.005. Because hypofractionated pre-operative radiosurgery achieved local control rates nearly identical to the 97 percent observed with cesium-131 brachytherapy, the authors noted that apparent local control variations may reflect single-fraction dose de-escalation rather than intrinsic technological superiority.
Evaluations of post-treatment adverse events revealed low overall frequencies of leptomeningeal disease and radiation necrosis across both interventional paradigms. Pooled leptomeningeal disease occurred in 5.1 percent of patients following pre-operative stereotactic radiosurgery across fourteen studies and in 9.1 percent following intraoperative cesium-131 brachytherapy across two reporting studies, demonstrating no statistically significant disparity with a p-value of 0.088. Radiation necrosis occurred in 5.2 percent of patients receiving pre-operative stereotactic radiosurgery across twelve studies and in 0.7 percent across four cesium-131 brachytherapy cohorts, yielding a p-value of 0.326. All five observed brachytherapy radiation necrosis events originated within the randomized Radiation One and Done Study, whereas the remaining three brachytherapy cohorts recorded zero necrosis occurrences, precluding an estimable sensitivity model excluding that trial.
Assessment of survival data revealed comparable systemic outcomes across both treatment modalities, reflecting the dominant influence of extracranial systemic disease progression on patient longevity. The median overall survival, calculated as the median of reported study-level medians, was 14.4 months for pre-operative stereotactic radiosurgery across ten studies and 15.6 months for cesium-131 brachytherapy across four studies. Within the brachytherapy cohorts, study-level medians ranged from 5.9 months to 42.5 months, with the upper threshold corresponding to the modified intention-to-treat population of the Radiation One and Done Study. When excluding that specific randomized trial estimate, the median overall survival range for brachytherapy cohorts narrowed to between 5.9 and 20.1 months, aligning closely with the observed 6.3 to 26.4 month survival range documented among pre-operative radiosurgery cohorts.
The study authors highlighted several methodological limitations inherent to synthesizing non-randomized and single-arm clinical literature. The evidence base compared single-arm cohorts across disparate publications rather than direct internal trial arms, leaving the findings susceptible to unmeasured variations in patient selection, systemic targeted therapies, and radiological follow-up intervals. Local failure criteria varied across included studies, spanning RANO-BM guidelines, new nodular enhancement, local investigator judgment, and centralized review. Additionally, eleven of eighteen local control counts relied on reconstructed actuarial estimates, assigning full-cohort weights to censored subjects and artificially inflating between-study variance within the brachytherapy subgroup. Consequently, the investigators emphasized that while both pre-operative radiosurgery and cesium-131 brachytherapy demonstrate excellent local efficacy, prospective randomized trials remain necessary to define their specific clinical indications.
Subject of Research: Comparative meta-analysis of pre-operative stereotactic radiosurgery versus intraoperative cesium-131 brachytherapy for resected brain metastases
Article Title: Pre-operative stereotactic radiosurgery versus intraoperative cesium-131 brachytherapy for resected brain metastases: a systematic review and meta-analysis
Article References: Kite, T., Mahmoudi, D. A., Singh, E., Knox, H., Gupta, B., Whiting, A. C., Karlovits, S., Wegner, R. E., Williams, B., & Shepard, M. J. (2026). Pre-operative stereotactic radiosurgery versus intraoperative cesium-131 brachytherapy for resected brain metastases: a systematic review and meta-analysis. Journal of Neuro-Oncology, 180(2), Article 40. https://doi.org/10.1007/s11060-026-05870-3
Image Credits: AI Generated
DOI: 10.1007/s11060-026-05870-3
Keywords: brain metastases, stereotactic radiosurgery, cesium-131 brachytherapy, radiation oncology, neurosurgical oncology, systematic review, meta-analysis, local control, Pre-operative, stereotactic, radiosurgery, versus
News Source: Cassandra Pierce. (November 9, 2026). Radiation Strategies Evaluated for Treating Resected Brain Metastases. Scienmag.



